Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus

ClinicalTrials.gov ID: NCT00285779

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00285779. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 3:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose is to assess the response of subjects to etanercept (as compared to placebo) in treating the physical signs of mucosal and cutaneous lichen planus. The investigators also wish to assess the effect of etanercept on disease-related itching, pain, and serious adverse events in patients with lichen planus.

Study identification

NCT ID
NCT00285779
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Stanford University
Other
Enrollment
27 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 2006 (Type not available)
Primary completion
Nov 2009 (Actual)
Completion
Nov 2009 (Actual)
Last update posted
Mar 21, 2018

2006 – 2009

United States locations

U.S. sites
12
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
Stanford University Medical Center Stanford California 94305 —
Emory University Atlanta Georgia 30322 —
University of Louisville Louisville Kentucky 40202 —
Tufts - New England Medical Center Boston Massachusetts 02111 —
David Fivenson, M.D. Dermatology, PLLC Ann Arbor Michigan 48103 —
University of Michigan Ann Arbor Michigan 48109 —
Mount Sinai School of Medicine New York New York 10029 —
Wake Forest University School of Medicine Winston-Salem North Carolina 26157 —
University Hospitals of Cleveland Cleveland Ohio 44106 —
Cleveland Clinic Foundation Cleveland Ohio 44195 —
Wright State University School of Medicine Dayton Ohio 45408 —
Oregon Health & Science University Portland Oregon 97239 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00285779, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 21, 2018 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.